CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Capecitabine and Oxaliplatin (XELOX) for the Treatment of Patients with Metastatic Gastric Cancer and Severe Liver Dysfunction
Seung Jae Hwang, Jong Won Park, Sehe Dong Lee, Gyong Jung Kim, Cheol Ho Sin, Seung-Hyun Nam, Bong-Seog Kim
Korean J Intern Med. 2006;21(4):252-255.   Published online 2006 December 31    DOI: https://doi.org/10.3904/kjim.2006.21.4.252

Excel Download

Capecitabine and Oxaliplatin (XELOX) for the Treatment of Patients with Metastatic Gastric Cancer and Severe Liver Dysfunction
The Korean Journal of Internal Medicine. 2006;21(4):252   Crossref logo
Link1 Link2 Link3

669 PUBLICATION Capecitabine and oxaliplatin (XELOX) as first-line treatment for elderly patients (pts) with advanced / metastatic colorectal cancer (MCRC)
European Journal of Cancer Supplements. 2005;3(2):190   Crossref logo
Link1 Link2

PCN22 ECONOMIC ANALYSIS OF CAPECITABINE PLUS OXALIPLATIN (XELOX) VERSUS FLUOROURACIL/LEUCOVORIN PLUS OXALIPLATIN (FOLFOX) IN THE TREATMENT OF ADVANCED GASTRIC CANCER IN CHINA
Value in Health. 2010;13(7):A514   Crossref logo
Link1 Link2

3012 ORAL Capecitabine + oxaliplatin (XELOX) vs. 5-FU/LV + oxaliplatin (FOLFOX4) as second-line treatment for patients with metastatic colorectal cancer (MCRC): Phase III trial results
European Journal of Cancer Supplements. 2007;5(4):238-239   Crossref logo
Link1 Link2

636 POSTER Initial safety findings from a phase III study of capecitabine (X) plus oxaliplatin (XELOX) vs. infusional 5-FU/LV plus oxaliplatin (FOLFOX-6) in first-line treatment of patients (pts) with metastatic colorectal cancer (MCRC)
European Journal of Cancer Supplements. 2005;3(2):179-180   Crossref logo
Link1 Link2

3546 POSTER (XELOX)Capecitabine plus Oxaliplatin: clinical efficacy and safety in first-line treatment for metastatic gastric cancer
European Journal of Cancer Supplements. 2007;5(4):273   Crossref logo
Link1 Link2

PCN66 ECONOMIC ANALYSIS OF CAPECITABINE PLUS OXALIPLATIN (XELOX) VERSUS FLUOROURACIL/LEUCOVORIN PLUS OXALIPLATIN (FOLFOX) IN THE TREATMENT OF ADVANCED COLON-RECTUM CANCER IN CHINA
Value in Health. 2010;13(7):A263   Crossref logo
Link1 Link2

Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer
International Journal of Cancer. 2010;128(3):682-690   Crossref logo
Link1 Link2

5-Fluorouracil Leucovorin and Oxaliplatin (FOLFOX) in the Treatment of Metastatic Colon Cancer with Severe Liver Dysfunction
Oncology. 2004;67(3-4):222-224   Crossref logo
Link1 Link2

EC3 COST-MINIMIZATION ANALYSIS OF CAPECITABINE + OXALIPLATIN (XELOX) VS. INFUSIONAL 5-FU/LV + OXALIPLATIN (FOLFOX-6) AS FIRST-LINE TREATMENT FOR METASTATIC COLORECTAL CANCER (MCRC) IN THE FRENCH SETTING
Value in Health. 2007;10(6):A233   Crossref logo
Link1 Link2

This metadata service is kindly provided by CrossRef from May 29, 2014. Korean J Intern Med has participated in CrossRef Text and Data Mining service since August 31, 2015.